Immusmol develops small molecule antibodies for research, diagnostics and therapy.

Combining 25 years of experience in antigen design, we offer to target low molecular weight molecules, which are not usually addressed by antibodies, such as amino acid metabolites, lipids, saccharids, toxins, pesticide residues, small molecule drugs, ... 

Compatible with existing antibody-based technologies, our small molecule antibodies can serve for:

> VISUALIZATION: Small molecule antibodies currently represent the only applicable technology for the visualization of small molecules in cells and tissues by IF or IHC.

> QUANTIFICATION: Combined with ELISA/EIA technologies, small molecule antibodies enable rapid and robust detection of small molecules in biological samples (an attractive alternative to mass-spec and aptamer-based technologies).

> MODULATION: Small molecules represent a vast class of neglected drug targets. ImmuSmol is currently developing a pipeline of proprietary monoclonal antibodies interfering with endogenous small molecules involved in cancer and CNS disorders.

Biotechnology

Health Diagnostics

Life Sciences

Immusmol

Immusmol's headquarters in Bordeaux, France

Immusmol

Org chart

Teams

Offices

Similar companies